ATE385781T1 - Montelukast-granulatformulierung - Google Patents

Montelukast-granulatformulierung

Info

Publication number
ATE385781T1
ATE385781T1 AT02801836T AT02801836T ATE385781T1 AT E385781 T1 ATE385781 T1 AT E385781T1 AT 02801836 T AT02801836 T AT 02801836T AT 02801836 T AT02801836 T AT 02801836T AT E385781 T1 ATE385781 T1 AT E385781T1
Authority
AT
Austria
Prior art keywords
montelukast
granular formulation
granular
formulation
relates
Prior art date
Application number
AT02801836T
Other languages
English (en)
Inventor
Brian Down
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE385781(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of ATE385781T1 publication Critical patent/ATE385781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02801836T 2001-10-26 2002-10-22 Montelukast-granulatformulierung ATE385781T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33954901P 2001-10-26 2001-10-26

Publications (1)

Publication Number Publication Date
ATE385781T1 true ATE385781T1 (de) 2008-03-15

Family

ID=23329547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801836T ATE385781T1 (de) 2001-10-26 2002-10-22 Montelukast-granulatformulierung

Country Status (26)

Country Link
US (2) US20030096840A1 (de)
EP (1) EP1441701B1 (de)
JP (1) JP4420671B2 (de)
KR (1) KR101094084B1 (de)
CN (1) CN100591329C (de)
AT (1) ATE385781T1 (de)
AU (1) AU2002333134B2 (de)
BR (1) BR0213477A (de)
CA (1) CA2463947C (de)
CY (1) CY1107400T1 (de)
DE (1) DE60225040T2 (de)
DK (1) DK1441701T3 (de)
EC (1) ECSP045082A (de)
EG (1) EG24380A (de)
ES (1) ES2298431T3 (de)
HR (1) HRP20040367B1 (de)
HU (1) HUP0401670A3 (de)
IL (1) IL161299A0 (de)
MX (1) MXPA04003856A (de)
MY (1) MY148466A (de)
NO (1) NO20042167L (de)
PE (1) PE20030638A1 (de)
PT (1) PT1441701E (de)
SI (1) SI1441701T1 (de)
WO (1) WO2003035036A1 (de)
ZA (1) ZA200402584B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
SI1863476T1 (sl) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
AU2006317530B2 (en) 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
EP1976522B2 (de) 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische zusammensetzung mit montelukast
SI1818057T1 (sl) * 2006-02-09 2010-08-31 Teva Pharma Stabilne farmacevtske formulacije montelukast natrija
US8106040B2 (en) 2006-09-26 2012-01-31 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
EP2262536A4 (de) * 2008-03-26 2013-07-03 Taro Pharmaceuticals North America Inc Stabilisierende lipidzusammensetzungen für orale pharmazeutische wirkstoffe
PT2296686E (pt) 2008-05-21 2014-05-23 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado por noctúria
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
WO2009153305A2 (en) * 2008-06-19 2009-12-23 Sandoz Ag Pharmaceutical compositions of montelukast sodium
JP5650532B2 (ja) * 2008-08-18 2015-01-07 三菱商事フードテック株式会社 新規マンニトール打錠用賦形剤
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
RU2566269C2 (ru) 2010-03-29 2015-10-20 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 孟鲁司特钠脂质体固体制剂
US9102665B2 (en) 2011-07-26 2015-08-11 Sun Pharma Advanced Research Company Ltd. Cysteinyl leukotriene antagonists
BR112014005134A2 (pt) 2011-09-16 2017-04-18 Ferring Bv composição farmacêutica de dissolução rápida
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
EP3275466A1 (de) 2012-07-12 2018-01-31 Ferring B.V. Diclofenacformulierungen
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) * 2012-09-12 2014-03-13 Glenmark Generics Ltd. Stable pharmaceutical composition of saxagliptin
CN103520129B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 一种孟鲁斯特钠脉冲释放制剂
CN103520130B (zh) * 2013-10-15 2020-08-04 天垚医药科技发展（上海）有限公司 孟鲁斯特钠择时控释片及其制备方法
CN103520136B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 孟鲁斯特钠脉冲胶囊及其制备方法
CN104644564A (zh) * 2013-11-25 2015-05-27 天津汉瑞药业有限公司 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN103720672B (zh) * 2014-01-26 2016-03-16 新疆特丰药业股份有限公司 孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
WO2016148455A2 (ko) * 2015-03-13 2016-09-22 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) * 2015-04-20 2019-03-27 高田製薬株式会社 モンテルカストナトリウム顆粒製剤
CN107595783A (zh) * 2017-06-01 2018-01-19 合肥远志医药科技开发有限公司 一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) * 2017-11-29 2019-06-04 扬子江药业集团有限公司 一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 一种孟鲁司特钠药物组合物
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CN111110679A (zh) * 2018-10-31 2020-05-08 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) * 2020-01-19 2020-06-09 安徽省先锋制药有限公司 一种孟鲁司特钠颗粒制剂方法
US11844792B2 (en) * 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) * 2020-07-29 2022-05-06 浙江诺得药业有限公司 一种孟鲁司特钠固体分散体、其制备方法及其应用
CN114224847B (zh) * 2021-12-07 2023-09-15 哈尔滨珍宝制药有限公司 一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) * 2022-02-24 2022-05-03 佑华医药科技有限公司 一种孟鲁司特钠颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
CA1338596C (en) 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
ES2058546T3 (es) 1988-09-30 1994-11-01 Rhone Poulenc Rorer Ltd Formulaciones farmaceuticas granulares.
ATE99545T1 (de) * 1989-03-29 1994-01-15 Takeda Chemical Industries Ltd Zusammensetzung mit einer verbindung der vitamin b-gruppe und ihre herstellung.
JP2800242B2 (ja) 1989-03-30 1998-09-21 大正製薬株式会社 粒剤の製造方法
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH0967247A (ja) 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd 均一な微粒子製剤の製造方法
JPH11514382A (ja) * 1995-11-02 1999-12-07 メルク フロスト カナダ アンド カンパニー 新規な湿粒法
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
IL136461A0 (en) 1997-12-23 2001-06-14 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6221880B1 (en) * 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20030031720A1 (en) 2000-02-24 2003-02-13 Tobias Laich Method for producing pharmaceutical dosage forms
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
MY148466A (en) 2013-04-30
HUP0401670A3 (en) 2008-08-28
WO2003035036A1 (en) 2003-05-01
JP2005510497A (ja) 2005-04-21
DK1441701T3 (da) 2008-05-26
NO20042167L (no) 2004-05-25
EP1441701A1 (de) 2004-08-04
SI1441701T1 (sl) 2008-08-31
BR0213477A (pt) 2004-11-03
IL161299A0 (en) 2004-09-27
MXPA04003856A (es) 2004-07-08
DE60225040D1 (de) 2008-03-27
PE20030638A1 (es) 2003-07-21
JP4420671B2 (ja) 2010-02-24
HRP20040367A2 (xx) 2005-06-30
US8007830B2 (en) 2011-08-30
ECSP045082A (es) 2004-06-28
DE60225040T2 (de) 2009-02-26
US20030096840A1 (en) 2003-05-22
US20080131516A1 (en) 2008-06-05
KR20040047961A (ko) 2004-06-05
KR101094084B1 (ko) 2011-12-15
CA2463947A1 (en) 2003-05-01
EP1441701B1 (de) 2008-02-13
AU2002333134B2 (en) 2007-08-02
CN100591329C (zh) 2010-02-24
HUP0401670A2 (hu) 2008-05-28
HRP20040367B1 (en) 2012-07-31
ZA200402584B (en) 2005-06-29
EG24380A (en) 2009-04-05
ES2298431T3 (es) 2008-05-16
PT1441701E (pt) 2008-04-07
CY1107400T1 (el) 2012-12-19
CA2463947C (en) 2009-05-19
CN1575163A (zh) 2005-02-02

Similar Documents

Publication Publication Date Title
ATE385781T1 (de) Montelukast-granulatformulierung
SE0203713D0 (sv) Novel compounds
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CO5590918A2 (es) Formulaciones
EA199900373A2 (ru) Фармацевтические композиции
ATE296619T1 (de) Feste orale dosierungsform von simethicon
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
ME00454B (me) Nova so perindoprila i farmaceutske kompozicije koje sadrže tu so
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
SE9901077D0 (sv) Novel use
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
NO20063293L (no) Farmasoytiske forbindelser
SE9801494D0 (sv) Novel use
SE0200657D0 (sv) Novel Formulation
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
TNSN06013A1 (en) Semi-solid systems containing azetidine derivatives
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA04003297A (es) Derivados novedosos de benzotiacina su preparacion y uso.
TW200603801A (en) Novel dialkoxy-imidazopyridines
DE60102704D1 (de) Trioxepan verbindungen
HN2001200000A (es) Suspension de ziprasidona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441701

Country of ref document: EP